+

US20080311035A1 - Diagnostic Agents For Positron Emission Imaging Using Radiolabeled Halogenated Xanthenes - Google Patents

Diagnostic Agents For Positron Emission Imaging Using Radiolabeled Halogenated Xanthenes Download PDF

Info

Publication number
US20080311035A1
US20080311035A1 US12/193,916 US19391608A US2008311035A1 US 20080311035 A1 US20080311035 A1 US 20080311035A1 US 19391608 A US19391608 A US 19391608A US 2008311035 A1 US2008311035 A1 US 2008311035A1
Authority
US
United States
Prior art keywords
radiolabeled
halogenated xanthene
agents
halogenated
rose bengal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/193,916
Inventor
Timothy C. Scott
H. Craig Dees
Eric A. Wachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provectus Pharmatech Inc
Original Assignee
Provectus Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provectus Pharmatech Inc filed Critical Provectus Pharmatech Inc
Priority to US12/193,916 priority Critical patent/US20080311035A1/en
Publication of US20080311035A1 publication Critical patent/US20080311035A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/0412Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom

Definitions

  • PET positron emission tomography
  • PET imaging is commonly used to obtain non-invasive information about internal body structures and tissues and the function and health of such structures and tissues.
  • PET uses a metabolically active molecule and a short-lived radioactive tracer isotope (to radiolabel the active molecule) as a diagnostic agent. The isotope decays by emitting a positron.
  • a PET diagnostic agent When administered to the body, it is retained or accumulates in certain tissues of interest, thereby facilitating imaging of those tissues based upon detection of gamma ray photons produced upon annihilation of positrons emitted from the radiolabeled PET diagnostic agent. Such annihilation occurs when an emitted positron collides with an electron present in the vicinity of emission, resulting in production of two 511 keV photons that are emitted in nearly opposite directions.
  • PET diagnostic agents are radiolabeled with (i.e., contain) one or more atoms that exhibit positron emission (such as certain isotopes of carbon, nitrogen, oxygen, fluorine, or rubidium, including 11 C, 13 N, 15 O, 18 F, and 82 Rb).
  • positron emission such as certain isotopes of carbon, nitrogen, oxygen, fluorine, or rubidium, including 11 C, 13 N, 15 O, 18 F, and 82 Rb.
  • the effects of the emitted positrons i.e., the subsequently emitted gamma ray photons
  • the results are then read by a nuclear medicine physician or radiologist to interpret the results in terms of the patient's diagnosis and treatment.
  • the present invention is directed to certain diagnostic agents for PET imaging and methods for using such agents exhibiting positron emission.
  • a primary component of such diagnostic agent is a halogenated xanthene or a functional derivative of a halogenated xanthene that has been radiolabeled with one or more positron emitting isotopes of carbon, oxygen, fluorine, chlorine, bromine, or iodine, including 10 C, 11 C, 13 O, 14 O, 15 O, 17 F, 18 F, 32 Cl, 33 Cl, 34 Cl, 74 Br, 75 Br, 76 Br, 77 Br, 78 Br, 117 I, 118 I, 119 I, 120 I, 121 I, 122 I, 124 I, 126 I, and 128 I.
  • this radiolabeled halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal.
  • diagnostic agent is a radiolabeled halogenated xanthene.
  • FIG. 1 a is an illustration of the chemical structure of a halogenated xanthene
  • FIG. 1 b is an illustration of the chemical structure of Rose Bengal.
  • a primary component of such diagnostic agent is a halogenated xanthene or a functional derivative of a halogenated xanthene that has been radiolabeled with one or more positron emitting isotopes of carbon, oxygen, fluorine, chlorine, bromine, or iodine, including 10 C, 11 C, 13 O, 14 O, 15 O, 17 F, 18 F, 32 Cl, 33 Cl, 34 Cl, 74 Br, 75 Br, 76 Br, 77 Br, 78 Br, 117 I, 118 I, 119 I, 120 I, 121 I, 122 I, 124 I, 126 I, and 128 I.
  • this radiolabeled halogenated xanthene is Rose Bengal (i.e., 4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) or a functional derivative of Rose Bengal.
  • the halogenated xanthenes constitute a family of extremely useful agents that can be selectively and safely delivered at high concentrations to certain tissues. Certain properties of the halogenated xanthenes are described in U.S. Ser. No. 09/184,388, filed on Nov. 2, 1998, in U.S. Ser. No. 09/216,787, filed on Dec. 21, 1998, in U.S. Ser. No. 09/635,276, filed on Aug. 9, 2000, in U.S. Ser. No. 09/799,785, filed on Mar. 6, 2001, in U.S. Ser. No. 09/817,448, filed on Mar. 26, 2001, in U.S. Ser. No. 09/900,355, filed on Jul. 6, 2001, and in U.S. Ser. No.
  • the halogenated xanthenes are characterized by a low cytotoxicity (toxicity to cells) at low concentration, a propensity for selective concentration or retention in certain tissues and cells, a high cytotoxicity upon such concentration or retention, and by chemical and physical properties that are substantially unaffected by the local chemical environment or by the attachment of functional derivatives at positions R 1 and R 2 described below.
  • FIG. 1 a The generalized chemical structure of the halogenated xanthenes is illustrated in FIG. 1 a , where the symbols X, Y, and Z represent various elements present at the designated positions, and the symbols R 1 and R 2 represent various functionalities present at the designated positions.
  • FIG. 1 b The chemical structure of a specific example of a halogenated xanthene, Rose Bengal, is illustrated in FIG. 1 b . Physical properties of representative halogenated xanthenes are summarized in attached Table 1.
  • the halogenated xanthenes have the empirical formula, C 20 H n O 5 F a Cl b Br c I d ,R 1 ,R 2 , where n ⁇ 2, and a, b, c, and d are integers greater than or equal to zero.
  • the empirical formula for the disodium salt of Rose Bengal is C 20 H 2 O 5 F 0 Cl 4 Br 0 I 4 ,R 1 ,R 2 , where R 1 and R 2 each represent a sodium atom, or, more simply, C 20 H 2 O 5 Cl 4 I 4 ,Na 2 .
  • the halogenated xanthenes are useful as food dyes, biological stains, photosensitizers (i.e. agents which are used with light for photodynamic imaging or treatment as for example disclosed in U.S. Ser. No. 09/635,276 and 09/799,785), radiosensitizers (i.e., agents that are used with applied ionizing radiation for imaging and radiation treatment as for example disclosed in U.S. Ser. No. 09/216,787 and 09/817,448), and as chemoablative or chemotherapeutic agents (as for example disclosed in U.S. Ser. No. 09/900,355).
  • photosensitizers i.e. agents which are used with light for photodynamic imaging or treatment as for example disclosed in U.S. Ser. No. 09/635,276 and 09/799,785
  • radiosensitizers i.e., agents that are used with applied ionizing radiation for imaging and radiation treatment as for example disclosed in U.S.
  • halogenated xanthenes exhibit selective retention in certain types of tissue, especially those exhibiting cancerous or precancerous conditions (i.e., neoplasia, dysplasia, and hyperplasia), as disclosed in U.S. Ser. No. 09/635,276, 09/799,785, 09/216,787, 09/817,448, and 09/900,355.
  • Such retention can be useful for diagnosis (for example, using x-ray computed tomography or ultrasound imaging) and for therapy (for example, using photodynamic, therapy or radiosensitization).
  • the present inventors have now discovered new isotopically-labeled (i.e., radiolabeled) members of the halogenated xanthene family that are capable of serving as diagnostic agents for PET imaging. More specifically, Applicants have created new halogenated xanthene compounds wherein a halogenated xanthene or a functional derivative of a halogenated xanthene has been radiolabeled with one or more positron emitting isotope of carbon, oxygen, fluorine, chlorine, bromine, or iodine, including 10 C, 11 C, 13 O, 14 O, 15 O, 17 F, 18 F, 32 Cl, 33 Cl, 34 Cl, 74 Br, 75 Br, 76 Br, 77 Br, 78 Br, 117 I, 118 I, 119 I, 120 I, 121 I, 122 I, 124 I, 126 I, and 128 I.
  • Radioisotopes such as for example the preferred radioisotopes of bromine or iodine (i.e., 74 Br, 75 Br, 76 Br, 77 Br, 78 Br, 117 I, 118 I, 119 I, 120 I, 121 I, 122 I, 124 I, 126 I, and 128 I), can be achieved by using standard halogen exchange methods, such as those taught in Serafini, supra.
  • radiolabeling can be achieved using radiolabeled starting materials in the synthesis of the desired halogenated xanthene (such as for example radiolabeled resorcinol or a radiolabeled phthalic anhydride), thereby directly synthesizing the radiolabeled xanthene.
  • radiolabeled starting materials such as for example radiolabeled resorcinol or a radiolabeled phthalic anhydride
  • These preferred longer-lived positron emitting isotopes include 11 C, 15 O, 18 F, 34 Cl, 74 Br, 75 Br, 76 Br, 77 Br, 78 Br, 117 I, 118 I, 119 I, 120 I, 121 I, 122 I, 124 I, 126 I, and 128 I. Because the distance traveled by the emitted positron prior to annihilation adversely affects image resolution (where traveled distance is proportional to positron energy), those longer-lived isotopes emitting lower energies are more preferred. Hence, the more preferred longer-lived, lower-energy positron emitting isotopes include 11 C, 18 F, 75 Br, 77 Br, 121 I, 124 I, and 126 I.
  • a diagnostic agent containing a halogenated xanthene radiolabeled with one or more of the aforementioned positron emitting elements can be used as a diagnostic agent for PET.
  • one preferred embodiment of the present invention is a diagnostic agent that contains, as an active ingredient at a concentration of from greater than approximately 0.001° to less than approximately 20%, at least one halogenated xanthene radiolabeled with one or more positron emitting isotope selected from the group of 10 C, 11 C, 13 O, 14 O, 15 O, 17 F, 18 F, 32 Cl, 33 Cl, 34 Cl, 74 Br, 75 Br, 76 Br, 77 Br, 78 Br, 117 I, 118 I, 119 I, 120 I, 121 I, 122 I, 124 I, 126 I, and 128 I (i.e., a radiolabeled halogenated xanthene).
  • at least one halogenated xanthene radiolabeled with one or more positron emitting isotope selected from the group of 10 C, 11 C, 13 O, 14 O, 15 O, 17 F, 18 F, 32 Cl, 33 Cl, 34 Cl, 74 Br, 75 Br, 76 Br
  • this radiolabeled halogenated xanthene is radiolabeled with one or more longer-lived positron isotope selected from the group of 11 C, 15 O, 18 F, 34 Cl, 74 Br, 75 Br, 76 Br, 77 Br, 78 Br, 117 I, 118 I, 119 I, 120 I, 121 I, 122 I, 124 I, 126 I, and 128 I. It is further preferred that this radiolabeled halogenated xanthene is radiolabeled with one or more longer-lived, lower-energy positron emitting isotopes selected from the group of 11 C, 18 F, 75 Br, 77 Br, 121 I, 124 I, and 126 I.
  • this radiolabeled halogenated xanthene is radiolabeled Rose Bengal.
  • radiolabled halogenated xanthenes which can be used in the diagnostic agent of the present invention include one or more of the following:
  • radiolabel comprises incorporation of one or more positron emitting isotope selected from the group of 10 C, 11 C, 13 O, 14 O, 15 O, 17 F, 18 F, 32 Cl, 33 Cl, 34 Cl, 74 Br, 75 Br, 76 Br, 77 Br, 78 Br, 117 I, 118 I, 119 I, 120 I, 121 I, 122 I, 124 I, 126 I, and 128 I.
  • positron emission tomography is used to image, detect or otherwise observe the presence of a diagnostic agent that contains, at a concentration of from greater than approximately 0.001% to less than approximately 20%, at least one radiolabeled halogenated xanthene. It is further preferred that this diagnostic agent include the radiolabeled form of the halogenated xanthene Rose Bengal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.

Description

  • This application claims the benefit of U.S. provisional application No. 60/578,622 filed Jun. 10, 2004.
  • BACKGROUND OF THE INVENTION
  • The present invention is directed to new diagnostic agents, and methods of use of such agents, for medical imaging using positron emission tomography (PET). PET is a nuclear medicine imaging technique which produces a three dimensional image of the body. PET imaging is commonly used to obtain non-invasive information about internal body structures and tissues and the function and health of such structures and tissues. PET uses a metabolically active molecule and a short-lived radioactive tracer isotope (to radiolabel the active molecule) as a diagnostic agent. The isotope decays by emitting a positron. When a PET diagnostic agent is administered to the body, it is retained or accumulates in certain tissues of interest, thereby facilitating imaging of those tissues based upon detection of gamma ray photons produced upon annihilation of positrons emitted from the radiolabeled PET diagnostic agent. Such annihilation occurs when an emitted positron collides with an electron present in the vicinity of emission, resulting in production of two 511 keV photons that are emitted in nearly opposite directions. Typically, such PET diagnostic agents are radiolabeled with (i.e., contain) one or more atoms that exhibit positron emission (such as certain isotopes of carbon, nitrogen, oxygen, fluorine, or rubidium, including 11C, 13N, 15O, 18F, and 82Rb). The effects of the emitted positrons (i.e., the subsequently emitted gamma ray photons) are detected by a detection device located outside the body which typically converts raw data into two- or three-dimensional images of the region of interest. The results are then read by a nuclear medicine physician or radiologist to interpret the results in terms of the patient's diagnosis and treatment.
  • Considerable effort has been invested in development of PET diagnostic agents in an effort to improve contrast between various anatomical features, such as between cancerous and non-cancerous tissues. Continued progress in medical science mandates improved options in such diagnostic capability, which in turn mandates further development of improved diagnostic agents.
  • Therefore, it is one object of the present invention to meet these characteristics, to overcome the drawbacks in prior methods and agents and to provide an improvement over these prior methods and agents.
  • SUMMARY OF THE INVENTION
  • The present invention is directed to certain diagnostic agents for PET imaging and methods for using such agents exhibiting positron emission.
  • In a preferred embodiment, a primary component of such diagnostic agent is a halogenated xanthene or a functional derivative of a halogenated xanthene that has been radiolabeled with one or more positron emitting isotopes of carbon, oxygen, fluorine, chlorine, bromine, or iodine, including 10C, 11C, 13O, 14O, 15O, 17F, 18F, 32Cl, 33Cl, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I. In a further preferred embodiment, this radiolabeled halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal.
  • These invented agents can be used in a method for imaging human or animal tissue comprising the steps of:
  • administering a diagnostic agent to a patient, a portion of said diagnostic agent being retained in tissue of interest, said diagnostic agent emitting positrons; and
  • imaging said tissue based on the effects of said positrons emitted from the diagnostic agent,
  • wherein said diagnostic agent is a radiolabeled halogenated xanthene.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 a is an illustration of the chemical structure of a halogenated xanthene; and
  • FIG. 1 b is an illustration of the chemical structure of Rose Bengal.
  • DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENT
  • The present invention is directed to certain diagnostic agents for PET imaging and methods for using such agents exhibiting positron emission. In a preferred embodiment, a primary component of such diagnostic agent is a halogenated xanthene or a functional derivative of a halogenated xanthene that has been radiolabeled with one or more positron emitting isotopes of carbon, oxygen, fluorine, chlorine, bromine, or iodine, including 10C, 11C, 13O, 14O, 15O, 17F, 18F, 32Cl, 33Cl, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I. In a further preferred embodiment, this radiolabeled halogenated xanthene is Rose Bengal (i.e., 4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) or a functional derivative of Rose Bengal.
  • The halogenated xanthenes constitute a family of extremely useful agents that can be selectively and safely delivered at high concentrations to certain tissues. Certain properties of the halogenated xanthenes are described in U.S. Ser. No. 09/184,388, filed on Nov. 2, 1998, in U.S. Ser. No. 09/216,787, filed on Dec. 21, 1998, in U.S. Ser. No. 09/635,276, filed on Aug. 9, 2000, in U.S. Ser. No. 09/799,785, filed on Mar. 6, 2001, in U.S. Ser. No. 09/817,448, filed on Mar. 26, 2001, in U.S. Ser. No. 09/900,355, filed on Jul. 6, 2001, and in U.S. Ser. No. 10/314,840, filed on Dec. 9, 2002, which are herein incorporated by reference in their entirety. In general, the halogenated xanthenes are characterized by a low cytotoxicity (toxicity to cells) at low concentration, a propensity for selective concentration or retention in certain tissues and cells, a high cytotoxicity upon such concentration or retention, and by chemical and physical properties that are substantially unaffected by the local chemical environment or by the attachment of functional derivatives at positions R1 and R2 described below.
  • The generalized chemical structure of the halogenated xanthenes is illustrated in FIG. 1 a, where the symbols X, Y, and Z represent various elements present at the designated positions, and the symbols R1 and R2 represent various functionalities present at the designated positions. The chemical structure of a specific example of a halogenated xanthene, Rose Bengal, is illustrated in FIG. 1 b. Physical properties of representative halogenated xanthenes are summarized in attached Table 1. In general, the halogenated xanthenes have the empirical formula, C20HnO5FaClbBrcId,R1,R2, where n≧2, and a, b, c, and d are integers greater than or equal to zero. For example, the empirical formula for the disodium salt of Rose Bengal is C20H2O5F0Cl4Br0I4,R1,R2, where R1 and R2 each represent a sodium atom, or, more simply, C20H2O5Cl4I4,Na2.
  • In their non-radiolabeled form, the halogenated xanthenes are useful as food dyes, biological stains, photosensitizers (i.e. agents which are used with light for photodynamic imaging or treatment as for example disclosed in U.S. Ser. No. 09/635,276 and 09/799,785), radiosensitizers (i.e., agents that are used with applied ionizing radiation for imaging and radiation treatment as for example disclosed in U.S. Ser. No. 09/216,787 and 09/817,448), and as chemoablative or chemotherapeutic agents (as for example disclosed in U.S. Ser. No. 09/900,355). When labeled with certain gamma-emitting isotopes of iodine (i.e., 131I and 125I), one of the halogenated xanthenes (Rose Bengal) has proven useful for diagnosis of hepatic function based on either measurement of differential excretion or imaging of the pattern of gamma emission from such radiolabeled molecules (for example as disclose in Serafini et al., J. Nucl. Med. 16 (1975) 629-633).
  • The present inventors were part of a team that has previously discovered and disclosed that the halogenated xanthenes exhibit selective retention in certain types of tissue, especially those exhibiting cancerous or precancerous conditions (i.e., neoplasia, dysplasia, and hyperplasia), as disclosed in U.S. Ser. No. 09/635,276, 09/799,785, 09/216,787, 09/817,448, and 09/900,355. Such retention can be useful for diagnosis (for example, using x-ray computed tomography or ultrasound imaging) and for therapy (for example, using photodynamic, therapy or radiosensitization).
  • The present inventors have now discovered new isotopically-labeled (i.e., radiolabeled) members of the halogenated xanthene family that are capable of serving as diagnostic agents for PET imaging. More specifically, Applicants have created new halogenated xanthene compounds wherein a halogenated xanthene or a functional derivative of a halogenated xanthene has been radiolabeled with one or more positron emitting isotope of carbon, oxygen, fluorine, chlorine, bromine, or iodine, including 10C, 11C, 13O, 14O, 15O, 17F, 18F, 32Cl, 33Cl, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I. One skilled in the art can synthesize and produce these new compounds using known chemistry of the halogenated xanthenes with the additional information provided in this application. For example, the synthesis and production of non-radiolabeled halogenated xanthenes and the chemistry of such compounds is known. Labeling with radioisotopes, such as for example the preferred radioisotopes of bromine or iodine (i.e., 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I), can be achieved by using standard halogen exchange methods, such as those taught in Serafini, supra. For these radioisotopes and the other radioisotopes listed herein, radiolabeling can be achieved using radiolabeled starting materials in the synthesis of the desired halogenated xanthene (such as for example radiolabeled resorcinol or a radiolabeled phthalic anhydride), thereby directly synthesizing the radiolabeled xanthene.
  • The present inventors have further discovered that a halogenated xanthene or a functional derivative of a halogenated xanthene that has been radiolabeled with one or more positron emitting isotope of carbon, oxygen, fluorine, chlorine, bromine, or iodine, including 10C, 11C, 13O, 14O, 15O, 17F, 18F, 32Cl, 33Cl, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I, can be useful as the active substance in a diagnostic agent for PET imaging. This non-naturally-occurring, novel composition of matter will retain the desirable specificity, toxicity, and other salient pharmaceutical properties of the halogenated xanthenes, as discussed above. Some of the important physical properties of the preferred positron emitting isotopes of carbon, oxygen, fluorine, chlorine, bromine, and iodine are summarized in attached Table 2. Because positron emitting isotopes with very short half-lives may in general be impractical for use in diagnostic procedures due to logistic difficulties in their timely production and subsequent delivery to the patient, those isotopes exhibiting half-lives in excess of approximately one minute are preferred and are more useful. These preferred longer-lived positron emitting isotopes include 11C, 15O, 18F, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I. Because the distance traveled by the emitted positron prior to annihilation adversely affects image resolution (where traveled distance is proportional to positron energy), those longer-lived isotopes emitting lower energies are more preferred. Hence, the more preferred longer-lived, lower-energy positron emitting isotopes include 11C, 18F, 75Br, 77Br, 121I, 124I, and 126I.
  • Thus, a diagnostic agent containing a halogenated xanthene radiolabeled with one or more of the aforementioned positron emitting elements can be used as a diagnostic agent for PET.
  • Hence, one preferred embodiment of the present invention is a diagnostic agent that contains, as an active ingredient at a concentration of from greater than approximately 0.001° to less than approximately 20%, at least one halogenated xanthene radiolabeled with one or more positron emitting isotope selected from the group of 10C, 11C, 13O, 14O, 15O, 17F, 18F, 32Cl, 33Cl, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I (i.e., a radiolabeled halogenated xanthene). It is further preferred that this radiolabeled halogenated xanthene is radiolabeled with one or more longer-lived positron isotope selected from the group of 11C, 15O, 18F, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I. It is further preferred that this radiolabeled halogenated xanthene is radiolabeled with one or more longer-lived, lower-energy positron emitting isotopes selected from the group of 11C, 18F, 75Br, 77Br, 121I, 124I, and 126I.
  • It is further preferred that this radiolabeled halogenated xanthene is radiolabeled Rose Bengal.
  • Examples of radiolabled halogenated xanthenes which can be used in the diagnostic agent of the present invention include one or more of the following:
  • radiolabeled 4′,5′-Dichlorofluorescein;
  • radiolabeled 2′,7′-Dichlorofluorescein;
  • radiolabeled 4,5,6,7-Tetrachlorofluorescein;
  • radiolabeled 2′,4′,5′,7′-Tetrachlorofluorescein;
  • radiolabeled Dibromofluorescein;
  • radiolabeled Solvent Red 72;
  • radiolabeled Diiodofluorescein;
  • radiolabeled Eosin B;
  • radiolabeled Eosin Y;
  • radiolabeled Ethyl Eosin;
  • radiolabeled Erythrosin B;
  • radiolabeled Phloxine B;
  • radiolabeled Rose Bengal;
  • radiolabeled 4,5,6,7-Tetrabromoerythrosin;
  • radiolabeled Mono-, Di-, or Tribromoerythrosin;
  • radiolabeled Mono-, Di-, or Trichloroerythrosin;
  • radiolabeled Mono-, Di-, or Trifluoroerytbrosin;
  • radiolabeled 2′,7′-Dichloro-4,5,6,7-Tetrafluorofluorescein;
  • radiolabeled 2′,4,5,6,7,7′-Hexafluorofluorescein;
  • radiolabeled 4,5,6,7-Tetrafluorofluorescein,
  • radiolabeled 2′,4′,5,5′,6,7′-Hexaiodofluorescein;
  • radiolabeled 2′,4′,5,5′,7,7′-Hexaiodofluorescein;
  • radiolabeled 2′,4′,5′,6,7,7′-Hexaiodofluorescein;
  • radiolabeled 2′,4′,5,5′,6,7,7′-Heptaiodofluorescein;
  • radiolabeled 4-Chloro-2′,4′,5,5′,6,7′-hexaiodofluorescein;
  • radiolabeled 4-Chloro-2′,4′,5,5′,7,7′-hexaiodofluorescein;
  • radiolabeled 4-Chloro-2′,4′,5′,6,7,7′-hexaiodofluorescein;
  • radiolabeled 4-Chloro-2′,4′,5,5′,6,7,7′-heptaiodofluorescein;
  • radiolabeled 4,5-Dichloro-2′,4′,5′,6,7,7′-hexaiodofluorescein;
  • radiolabeled 4,6-Dichloro-2′,4′,5,5′,7,7′-hexaiodofluorescein; and
  • radiolabeled 4,7-Dichloro-2′,4′,5,5′,6,7′-hexaiodofluorescein,
  • wherein said radiolabel comprises incorporation of one or more positron emitting isotope selected from the group of 10C, 11C, 13O, 14O, 15O, 17F, 18F, 32Cl, 33Cl, 34Cl, 74Br, 75Br, 76Br, 77Br, 78Br, 117I, 118I, 119I, 120I, 121I, 122I, 124I, 126I, and 128I.
  • In an alternate preferred embodiment, positron emission tomography is used to image, detect or otherwise observe the presence of a diagnostic agent that contains, at a concentration of from greater than approximately 0.001% to less than approximately 20%, at least one radiolabeled halogenated xanthene. It is further preferred that this diagnostic agent include the radiolabeled form of the halogenated xanthene Rose Bengal.
  • This description has been offered for illustrative purposes only and is not intended to limit the invention of this application.
  • TABLE 1
    Physical properties of some example halogenated xanthenes
    (non-radiolabeled).
    Substitution
    Compound X Y Z R1 R2 MW (g)
    4′,5′-Dichlorofluorescein Cl H H Na Na 445
    2′,7′-Dichlorofluorescein H Cl H Na Na 445
    4,5,6,7-Tetrachlorofluorescein H H Cl H H 470
    2′,4′,5′,7′-Tetrachlorofluorescein Cl Cl H Na Na 514
    Dibromofluorescein Br H H Na Na 534
    Solvent Red 72 H Br H H H 490
    Diiodofluorescein I H H Na Na 628
    Eosin B NO2 Br H Na Na 624
    Eosin Y Br Br H Na Na 692
    Ethyl Eosin Br Br H C2H5 K 714
    Erythrosin B I I H Na Na 880
    Phloxine B Br Br Cl Na Na 830
    Rose Bengal I I Cl Na Na 1018
    4,5,6,7-Tetrabromoerythrosin I I Br Na Na 1195
  • TABLE 2
    Isotopes of relevance for PET with the halogenated xanthenes.
    Positron
    Emission Emission Energy
    Element Isotope Half-Life (MeV)
    Carbon 10C 19 sec 1.9
    11C 20 min 1.0
    Oxygen 13O 0.009 sec 6.4
    14O 71 sec 1.8
    15O 124 sec 1.7
    Fluorine 17F 66 sec 1.7
    18F 110 min 0.6
    Chlorine 32Cl 0.3 sec 9.5
    33Cl 2.5 sec 4.5
    34Cl 32 min 2.5
    Bromine 74Br 36 min 4.7
    75Br 1.7 hours 0.3
    76Br 16.1 hours 1.2-3.6
    77Br 57 hours 0.4
    78Br 6.4 min 1.9
    Iodine 117I 7 min
    118I 14 min 5.5
    119I 19 min
    120I 1.3 hours 2.1-4.0
    121I 2.1 hours 1.2
    122I 3.5 min 1.8-3.1
    124I 4.2 days 0.8-2.1
    126I 13 days 1.1
    128I 25 min

Claims (4)

1-7. (canceled)
8. A diagnostic agent comprising at least one positron emitting radiolabeled halogenated xanthene as a primary active component,
wherein said radiolabeled halogenated xanthene is a derivative of Rose Bengal having the formula C20H2O5F0Cl4Br0I4, R1,R2, where R1 or R2 are at least one targeting moiety attached to Rose Bengal, and
wherein said at least one targeting moiety is selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), amino acids, proteins, antibodies, ligands, haptens, carbohydrate receptors, carbohydrate complexing agents, lipid receptors, lipid complexing agents, protein receptors, protein complexing agents, chelators, short-chain aliphatic hydrocarbons, long-chain aliphatic hydrocarbons, and aromatic hydrocarbons.
9. The agent of claim 8 wherein said radiolabled halogenated xanthene is present in a concentration of greater than about 0.001% to less than about 20%.
10. (canceled)
US12/193,916 2004-06-10 2008-08-19 Diagnostic Agents For Positron Emission Imaging Using Radiolabeled Halogenated Xanthenes Abandoned US20080311035A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/193,916 US20080311035A1 (en) 2004-06-10 2008-08-19 Diagnostic Agents For Positron Emission Imaging Using Radiolabeled Halogenated Xanthenes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57862204P 2004-06-10 2004-06-10
US11/049,797 US7427389B2 (en) 2004-06-10 2005-02-03 Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes
US12/193,916 US20080311035A1 (en) 2004-06-10 2008-08-19 Diagnostic Agents For Positron Emission Imaging Using Radiolabeled Halogenated Xanthenes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/049,797 Continuation US7427389B2 (en) 2004-06-10 2005-02-03 Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes

Publications (1)

Publication Number Publication Date
US20080311035A1 true US20080311035A1 (en) 2008-12-18

Family

ID=35460751

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/049,797 Expired - Fee Related US7427389B2 (en) 2004-06-10 2005-02-03 Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes
US12/193,916 Abandoned US20080311035A1 (en) 2004-06-10 2008-08-19 Diagnostic Agents For Positron Emission Imaging Using Radiolabeled Halogenated Xanthenes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/049,797 Expired - Fee Related US7427389B2 (en) 2004-06-10 2005-02-03 Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes

Country Status (1)

Country Link
US (2) US7427389B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107337681A (en) * 2017-07-28 2017-11-10 厦门大学 A kind of superoxide anion probe and its preparation method and application

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427389B2 (en) * 2004-06-10 2008-09-23 Provectus Pharmatech, Inc. Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes
GB0613287D0 (en) * 2006-07-05 2006-08-16 Ge Healthcare Ltd Dye imaging agents
US8293208B2 (en) 2009-05-15 2012-10-23 The Governors Of The University Of Alberta Fluorinated fructose derivatives for PET imaging

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5240693A (en) * 1991-05-01 1993-08-31 University Of New Mexico Image enhancement by coadministration of biomodulators and structurally modified imaging agents
US6493570B1 (en) * 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US7338652B2 (en) * 2004-06-10 2008-03-04 Provectus Pharmatech, Inc. Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents
US7427389B2 (en) * 2004-06-10 2008-09-23 Provectus Pharmatech, Inc. Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB846674A (en) 1958-04-29 1960-08-31 Univ Kansas Res Foundation Xanthene compounds and dyestuffs and means of producing the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5240693A (en) * 1991-05-01 1993-08-31 University Of New Mexico Image enhancement by coadministration of biomodulators and structurally modified imaging agents
US6493570B1 (en) * 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US7338652B2 (en) * 2004-06-10 2008-03-04 Provectus Pharmatech, Inc. Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents
US7427389B2 (en) * 2004-06-10 2008-09-23 Provectus Pharmatech, Inc. Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107337681A (en) * 2017-07-28 2017-11-10 厦门大学 A kind of superoxide anion probe and its preparation method and application

Also Published As

Publication number Publication date
US20050276752A1 (en) 2005-12-15
US7427389B2 (en) 2008-09-23

Similar Documents

Publication Publication Date Title
CN1840531B (en) Porphyrin-based compounds for tumor imaging and photodynamic therapy
CN112851637B (en) PSMA inhibitor, compound, preparation method and application thereof
WO2011049405A2 (en) Optical imaging contrast agent, use and device thereof
JP2860157B2 (en) Method for producing radioactively labeled technetium chelate injection for renal function measurement
Blanco et al. Optical and nuclear imaging of glioblastoma with phosphatidylserine-targeted nanovesicles
CA1216288A (en) Radiolabeled tumor imaging agent and method of preparation
US20080311035A1 (en) Diagnostic Agents For Positron Emission Imaging Using Radiolabeled Halogenated Xanthenes
Hodolic et al. Safety and tolerability of 68 Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use
US4430319A (en) Radioactive iodine labeled phenolic amines
US7338652B2 (en) Methods for positron emission imaging with radiolabeled halogenated xanthenes diagnostic agents
EP1753467B1 (en) Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes and methods for positron emission imaging with radiolabeled halogenated xanthene diagnostic agents
US20240024519A1 (en) Radiopharmaceutical compositions of copper for targeted molecular imaging
El-Kawy et al. Preparation and evaluation of radiolabeled gliclazide parenteral nanoemulsion as a new tracer for pancreatic β-cells mass
RU2614235C2 (en) Osteotropic radiopharmaceuticals for pet imaging
Gholipour et al. Chelator-free radiolabeling of dextran with 68Ga for PET studies
KR102621851B1 (en) Porphyrin derivatives and Composition for imaging, diagnosing, or treating cancers
RU2817970C1 (en) Lyophilisate based on prostate-specific membrane antigen (psma) ligands for preparing a radiopharmaceutical composition in form of solution for injections for treating prostate cancer, radiopharmaceutical composition based on it for treating prostate cancer and method for preparing radiopharmaceutical composition
US20240336632A1 (en) Novel compound comprising ester group and uses thereof
ES2938415T3 (en) A radiolabeled compound of quaternary ammonium salt of a polycyclic aromatic amine, the use of the radiolabeled compound in a positron emission tomography diagnostic method, and a pharmaceutical composition containing the radiolabeled compound of the quaternary ammonium salt of a polycyclic aromatic amine
CA2593323C (en) Bridgehead labelled compounds and methods of using the same
Niculae et al. DETECTION OF SENTINEL LYMPH NODE-BASED ON SPECIFIC BINDING TO MANNOSE RECEPTORS
WO2011096374A1 (en) Novel iodobenzyl-bleomycin compound
Wolfstein Preoperative Parathyroid Localization by Superimposed Iodine-131 Toluidine Blue and Technetium-99m Pertechnetate Imaging
NL8002860A (en) ORGANOMETAL COMPLEX WITH GAMMA RADIATION EMITTING ISOTOPE.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载